FOXA1 plays a role in regulating secretoglobin 1a1 expression in the absence of CCAAT/enhancer binding protein activities in lung in vivo

Taketomo Kido, Takeshi Tomita, Minoru Okamoto, Yan Cai, Yoshimi Matsumoto, Charles Vinson, Yoshiro Maru, Shioko KimuraAmerican 2010 · DOI

TL;DR

This study reveals that while in vitro experiments suggest C/EBPs are the primary regulators of SCGB1A1 gene expression in lung cells, in vivo experiments show a surprising compensatory role for FOXA1 when C/EBPs are inhibited. This highlights the critical importance of in vivo studies for understanding gene regulation in complex biological systems.

What Problem Does This Paper Address?

The researchers are investigating the regulation of secretoglobin (SCGB) 1A1 gene expression in lung epithelial cells. SCGB1A1, also known as Clara cell secretory protein (CCSP), is a small protein with anti-inflammatory and immunomodulatory properties, primarily found in the lung. Previous in vitro studies pointed to CCAAT/enhancer-binding proteins (C/EBPs) as the main transcription factors controlling SCGB1A1 expression, with FOXA1 showing only a minor effect. However, the authors questioned whether these in vitro findings accurately reflect the complex regulatory mechanisms in vivo, especially in a multicellular organ like the lung where multiple transcription factors and cellular interactions are at play. They aimed to determine the in vivo role of C/EBPs in SCGB1A1 regulation and explore potential alternative regulatory pathways when C/EBPs are suppressed.

Methods

The core of the study involved using a genetically engineered mouse model. Specifically, they employed a tetracycline-inducible transgenic mouse line (CCSP-rtTA;TetO-A-C/EBP) where a dominant-negative form of C/EBP (A-C/EBP) could be specifically expressed in lung epithelial cells upon administration of doxycycline (Dox). This A-C/EBP protein interferes with the DNA-binding activity of all C/EBP family members, effectively creating a condition where C/EBP activity is suppressed in vivo.

Key techniques included:

  • Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR): Used extensively to measure mRNA levels of SCGB1A1, SCGB3A2, A-C/EBP, and various transcription factors (C/EBPs, FOXA1, FOXA2, NKX2-1, CYP2F2) in lung tissue.
  • Western Blotting: Employed to assess protein expression levels of SCGB1A1, SCGB3A2, C/EBPs, and FOXA1 in lung tissue.
  • Immunohistochemistry: Used to visualize the spatial expression patterns of SCGB1A1, C/EBPs, and FOXA1 within lung tissue sections, allowing for cell-level analysis.
  • Luciferase Reporter Assays: Performed in cultured COS-1 cells to investigate the transcriptional activity of the SCGB1A1 promoter under the influence of different combinations of transcription factors and the A-C/EBP construct.
  • Electrophoretic Mobility Shift Assay (EMSA): Utilized to directly assess the DNA-binding capabilities of C/EBPs and FOXA1 to specific sequences within the SCGB1A1 promoter, and to determine if A-C/EBP interferes with this binding.
  • Transfection Assays: Conducted in mtCC cells (a transformed mouse Clara cell line) to examine the effects of A-C/EBP expression on SCGB1A1 and other gene expressions in a controlled cellular environment.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from mouse models and cell culture experiments.

Key Insights and Ideas

  • In Vitro vs. In Vivo Discrepancy: The most striking finding is the stark contrast between in vitro and in vivo results. While in vitro studies strongly implicate C/EBPs as the primary drivers of SCGB1A1 expression, suppressing C/EBPs in vivo did not lead to a decrease in SCGB1A1 mRNA.
  • FOXA1 as a Compensatory Regulator: In the absence of functional C/EBPs, FOXA1 appears to step in and maintain SCGB1A1 expression. This suggests a flexible regulatory network where alternative factors can compensate for the loss of key regulators.
  • Importance of the Lung Microenvironment: The study underscores that gene regulation in a complex organ is not simply the sum of individual transcription factor activities in isolation. The cellular context, interactions, and potential compensatory mechanisms are crucial.
  • Protein Stabilization/Translation: While SCGB1A1 mRNA levels remained unchanged in vivo when C/EBPs were inhibited, protein levels showed an increase. This suggests that FOXA1 might also influence SCGB1A1 expression through post-transcriptional mechanisms like protein stabilization or increased translation.
  • A-C/EBP's Differential Effects: The dominant-negative A-C/EBP construct had different impacts in vitro (reducing SCGB1A1 mRNA) versus in vivo (not reducing SCGB1A1 mRNA, and even increasing protein levels). This highlights the limitations of solely relying on cell culture models.

Key Results

  • SCGB1A1 mRNA: In A-C/EBP transgenic mice fed Dox (inhibiting C/EBPs), SCGB1A1 mRNA levels did not decrease compared to control mice. This was contrary to expectations based on in vitro data.
  • SCGB3A2 mRNA: In contrast, SCGB3A2 mRNA levels were significantly reduced in A-C/EBP mice fed Dox, aligning with previous findings and confirming the effectiveness of the A-C/EBP model for C/EBP inhibition.
  • FOXA1 Protein: Western blot analysis showed an increase in FOXA1 protein levels in the lungs of A-C/EBP+ mice compared to controls.
  • SCGB1A1 Protein: Protein levels of SCGB1A1 were significantly higher in A-C/EBP+ mice fed Dox compared to controls, despite similar mRNA levels.
  • Promoter Activity: In vitro luciferase assays showed that C/EBPδ and C/EBPα significantly enhanced SCGB1A1 promoter activity, while FOXA1 had a smaller effect. However, when A-C/EBP was present, C/EBP activity was suppressed, while FOXA1's activity remained, and even enhanced promoter activity when combined with C/EBPs.
  • DNA Binding: EMSA confirmed that C/EBPs and FOXA1 bind to the SCGB1A1 promoter. Crucially, A-C/EBP interfered with C/EBP binding but did not affect FOXA1 binding.

Limitations and Future Work

  • In Vitro vs. In Vivo Discrepancy: The authors acknowledge the difficulty in fully explaining the discrepancy between in vitro and in vivo results. They suggest that the robust nature of in vitro transfection systems and the direct effect of A-C/EBP might differ from the multi-step processes involved in vivo.
  • Endogenous Transcription Factor Levels: The study notes that the endogenous levels of C/EBPs and FOXA1 in lung cells are not precisely known, making direct comparisons of their relative contributions challenging.
  • Protein Stabilization/Translation: The observed increase in SCGB1A1 protein without a corresponding increase in mRNA suggests post-transcriptional regulation. Further studies could investigate the specific mechanisms involved in protein stabilization or translation enhancement by FOXA1.
  • FOXA2 Role: Given that FOXA2 also binds to FOXA binding sites, the authors hypothesize it might behave similarly to FOXA1 in the absence of C/EBPs, suggesting future investigation into FOXA2's role.
  • Long-Term Homeostasis: The study speculates that long-term suppression of C/EBPs might alter lung homeostasis, potentially requiring higher levels of immunomodulatory proteins like SCGB1A1. Further research could explore these broader homeostatic impacts.
  • Subtle Histological Changes: While no major histological differences were observed, the possibility of subtle remodeling of airway cells due to long-term C/EBP suppression remains.

Summary updated

Abstract

Secretoglobin (SCGB) 1A1, also called Clara cell secretor protein (CCSP) or Clara cell-specific 10-kDa protein (CC10), is a small molecular weight secreted protein mainly expressed in lung, with anti-inflammatory/immunomodulatory properties. Previous in vitro studies demonstrated that CCAAT/enhancer-binding proteins (C/EBPs) are the major transcription factors for the regulation of Scbg1a1 gene expression, whereas FOXA1 had a minimum effect on the transcription. To determine the in vivo role of C/EBPs in the regulation of SCGB1A1 expression, experiments were performed in which A-C/EBP, a dominant-negative form of C/EBP that interferes with DNA binding activities of all C/EBPs, was specifically expressed in lung. Surprisingly, despite the in vitro findings, expression of SCGB1A1 mRNA was not decreased in vivo in the absence of C/EBPs. This may be due to a compensatory role assumed by FOXA1 in the regulation of Scgb1a1 gene expression in lung in the absence of active C/EBPs. This disconnect between in vitro and in vivo results underscores the importance of studies using animal models to determine the role of specific transcription factors in the regulation of gene expression in intact multicellular complex organs such as lung.
BibTeX
@inproceedings{kido2010foxa,
  author = {Taketomo Kido and Takeshi Tomita and Minoru Okamoto and Yan Cai and Yoshimi Matsumoto and Charles Vinson and Yoshiro Maru and Shioko Kimura},
  title = {{FOXA1 plays a role in regulating secretoglobin 1a1 expression in the absence of CCAAT/enhancer binding protein activities in lung in vivo}},
  booktitle = {American},
  year = {2010},
  doi = {10.1152/ajplung.00435.2009},
}
Figure